ERBB2 and breast cancer: Luminal BC: CDK4/6 inhibitors + ET;HER2+: trastuzumab + pertuzumab + docetaxel;TNBC: immune checkpoint inhibitors expressing PD-L1; Arm A continues systemic chemotherapy alone; Arm B followed the same treatment.